AVITA Therapeutics Appoints Kathy McGee as Chief Operating Officer
December 01 2020 - 8:00AM
AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative
medicine company that is developing and commercializing a
technology platform that enables point-of-care autologous skin
restoration for multiple unmet needs, announced today the
appointment of Kathy McGee as Chief Operating Officer, effective
December 1, 2020.
“Kathy’s extensive healthcare experience and industry insight
are a welcome addition to AVITA’s leadership team,” said Dr. Mike
Perry, AVITA Therapeutics’ Chief Executive Officer. “In particular
her broad operational experience within Regenerative Medicine will
be critically important as we seek to bring our pipeline products
through development and into the markets.”
Ms. McGee joins AVITA with over 25 years of biopharmaceutical
and life sciences experience, most recently serving as President of
CnA Consulting Group, which focuses on providing specialized
consulting services to the life sciences industry. Prior to CnA
Consulting, Ms. McGee was the Vice President of West Coast
Operations at Shire Pharmaceuticals Regenerative Medicine Division,
formerly Advanced BioHealing, where she was a part of the
leadership team responsible for manufacturing operations, strategic
planning, capital expansion, and real estate. At Advanced
BioHealing, Ms. McGee served as the Senior Vice President of
Operations and General Manager, with responsibility for the
company’s manufacturing operations in La Jolla, CA. She has also
held senior Operations leadership roles at Smith and Nephew and
Advanced Tissue Sciences. She earned her Bachelor of Science in
chemistry and mathematics from University College Galway Ireland,
and holds a Master’s degree in Business and Management from Webster
University.
Authorized for release by the Chief Executive Officer of AVITA
Therapeutics, Inc.
ABOUT AVITA THERAPEUTICS,
INC.AVITA Therapeutics is a regenerative medicine company
with a technology platform positioned to address unmet medical
needs in burns, chronic wounds, and aesthetics indications. AVITA
Therapeutics’ patented and proprietary collection and application
technology provides innovative treatment solutions derived from the
regenerative properties of a patient’s own skin. The medical
devices work by preparing a RES® REGENERATIVE EPIDERMAL SUSPENSION,
an autologous suspension comprised of the patient’s skin cells
necessary to regenerate natural healthy epidermis. This autologous
suspension is then sprayed onto the areas of the patient requiring
treatment.
AVITA Therapeutics’ first U.S. product, the RECELL® System, was
approved by the U.S. Food and Drug Administration (FDA) in
September 2018. The RECELL System is indicated for use in the
treatment of acute thermal burns in patients 18 years and older.
The RECELL System is used to prepare Spray-On Skin™ Cells using a
small amount of a patient’s own skin, providing a new way to treat
severe burns, while significantly reducing the amount of donor skin
required. The RECELL System is designed to be used at the point of
care alone or in combination with autografts depending on the depth
of the burn injury. Compelling data from randomized, controlled
clinical trials conducted at major U.S. burn centers and real-world
use in more than 8,000 patients globally, reinforce that the RECELL
System is a significant advancement over the current standard of
care for burn patients and offers benefits in clinical outcomes and
cost savings. Healthcare professionals should read the INSTRUCTIONS
FOR USE - RECELL® Autologous Cell Harvesting Device
(https://recellsystem.com/) for a full description of indications
for use and important safety information including
contraindications, warnings and precautions.
In international markets, our products are marketed under the
RECELL System brand to promote skin healing in a wide range of
applications including burns, chronic wounds and aesthetics. The
RECELL System is TGA-registered in Australia and received CE-mark
approval in Europe.To learn more, visit www.avitamedical.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTSThis letter includes forward-looking statements.
These forward-looking statements generally can be identified by the
use of words such as “anticipate,” “expect,” “intend,” “could,”
“may,” “will,” “believe,” “estimate,” “look forward,” “forecast,”
“goal,” “target,” “project,” “continue,” “outlook,” “guidance,”
“future,” other words of similar meaning and the use of future
dates. Forward-looking statements in this letter include, but are
not limited to, statements concerning, among other things, our
ongoing clinical trials and product development activities,
regulatory approval of our products, the potential for future
growth in our business, and our ability to achieve our key
strategic, operational and financial goal. Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain. Each forward- looking statement contained in
this letter is subject to risks and uncertainties that could cause
actual results to differ materially from those expressed or implied
by such statement. Applicable risks and uncertainties include,
among others, the timing of regulatory approvals of our products;
physician acceptance, endorsement, and use of our products; failure
to achieve the anticipated benefits from approval of our products;
the effect of regulatory actions; product liability claims; risks
associated with international operations and expansion; and other
business effects, including the effects of industry, economic or
political conditions outside of the company’s control. Investors
should not place considerable reliance on the forward-looking
statements contained in this letter. Investors are encouraged to
read our publicly available filings for a discussion of these and
other risks and uncertainties. The forward-looking statements in
this letter speak only as of the date of this release, and we
undertake no obligation to update or revise any of these
statements.
FOR FURTHER INFORMATION:
U.S. MediaSam Brown, Inc.Christy
CurranPhone +1 615 414 8668christycurran@sambrown.comO.U.S
MediaMonsoon CommunicationsRudi
MichelsonPhone +61 (0)3 9620 3333Mobile +61 (0)411 402
737rudim@monsoon.com.au |
Investors:Westwicke
PartnersCaroline CornerPhone +1 415 202
5678caroline.corner@westwicke.com |
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avita Medical (NASDAQ:RCEL)
Historical Stock Chart
From Sep 2023 to Sep 2024